Lysins: Multiple Gram-positive and Gram-negative lysins, with a focus on skin, lung, prosthetic joint, and vaginal infections. By comparison to other known lysins, Precisio's are more commercially viable: (1) lower MICs; (2) better stability, particularly Gram-negative lysins that are stable in blood plasma and lung extract; (3) higher levels of expression (improved “manufacturability"); and (3) lower COGs.

Amurins: Envelope-perforating peptides active against Gram-negative pathogens and nontuberculous mycobacteria, with a focus on lung infections. Exhibit range of hallmark antimicrobial properties, including rapid kill, antibiofilm effects, synergy with antibiotics, low resistance.

Precisio has Reduced Risk and Development Costs by: (1) Focusing on skin, lung, prosthetic joint, and vaginal infections, where there is significantly less toxicity and immunogenicity risk; (2) Focusing on low cost of goods, thereby able to address both Rx and consumer market opportunities; (3) Conducting animal tests and other pre-clinical work in Asia; and (4) Developing, in addition to Rx products, rapid-to-market consumer products to generate early cash flow. Several sales collaborations will be announced in Q3/Q4 2025.

Bactelide™: A phage product to prevent and treat topical infections which is ready to commence a Phase I/II clinical trial. Precisio will conduct this clinical trials in India.